Allogene Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLO research report →
Range $3.85 – $9
Price Chart
About the company
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
- CEO
- Zachary Roberts
- IPO
- 2018
- Employees
- 151
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ALLO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $217.48M
- P/E
- -1.06
- Fwd P/E
- 0.89
- PEG
- -0.02
- P/S
- 49.80
- P/B
- 0.59
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -4099.33%
- Net Margin
- -3759.98%
- ROE
- -49.84%
- ROIC
- -40.23%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-12,359,000-56277.3%
- Op Income
- $-206,933,000
- Net Income
- $-190,886,000+25.9%
- EPS
- $-0.87+34.1%
- OCF Growth
- +25.5%
- FCF Growth
- +25.6%
- 52W High
- $4.46
- 52W Low
- $0.62
- 50D MA
- $1.32
- 200D MA
- $1.93
- Beta
- 0.48
- RSI (14)
- 18
- Avg Volume
- 7.64M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Allogene said ALPHA3 is progressing well with stronger community-site interest and enrollment, while ALLO-329 remains an early but promising autoimmune program ahead of next week’s data readout.· November 5, 2026
- ALPHA3 enrollment is accelerating, with increased MRD screening, stronger investigator engagement, and new interest from community practices and Asia-Pacific sites.
- Management said cema-cel continues to look outpatient- and community-ready, including at sites with no prior CAR-T experience, based on a favorable safety profile so far.
- For ALPHA3, the company reiterated guidance for enrollment completion by the end of next year and a mid-2027 data update, while noting the DSMB could choose not to unblind based on the small alpha allocated.
- ALLO-329’s next dataset will include more patients, longer follow-up, three dose levels, and three conditioning approaches, with management highlighting no high-grade toxicities or IEC-HS to date.
- Management believes ALLO-329’s CD19/CD70 design and potential to reduce or eliminate chemotherapy-based lymphodepletion could be important differentiators in autoimmune disease.
The call did not provide quarter-specific revenue, EPS, or gross margin figures. Management instead focused on clinical progress and forward milestones. For ALPHA3, Allogene said enrollment is tracking toward completion by the end of next year, with a mid-2027 update planned on the primary endpoint of event-free survival; management also said the study remains under DSMB and FDA oversight, and the DSMB may decide not to unblind the data depending on the small amount of alpha assigned to that look. For ALLO-329, the company said expanded clinical and translational data will be presented next week and that to date there have been no high-grade toxicities or cases of IEC-HS, with the trial still early and internal go/no-go decisions ahead.
Zachary Roberts framed the quarter around a strategic reset: Allogene is trying to move CAR-T earlier and make it practical enough for community settings rather than relying on a traditional late-line development path. He emphasized that ALPHA3 is testing whether cema-cel can change when, where, and how CAR-T is delivered, and he repeatedly pointed to real-world barriers like site readiness, reimbursement, and treatment burden. His tone was confident and deliberate, but he also stressed discipline around trial integrity and said the company is still early in its decisions for ALLO-329.
Geoff Parker did not discuss detailed financial results on the call because this was a business update focused on clinical programs, and no revenue, EPS, cash, or margin figures were cited in the prepared remarks or Q&A. The only CFO-related commentary was a brief recognition of his retirement and a statement that financial operations and controls remain in place under Annie Yoshiyama, who has handled finance, corporate control, and accounting responsibilities since 2024. No capital allocation updates or balance-sheet metrics were provided.
Analysts pressed management on ALPHA3 enrollment pace, the significance of the mid-2027 EFS look, and whether the small alpha allocation could prevent an early unblinded stop; management said it is pleased with recent site productivity but will follow DSMB/FDA guidance and prioritize trial integrity. There were also questions about whether cema-cel can be taught safely to community practices, and Roberts said many sites already know bispecific toxicities and are being trained with medication support for CRS or other events. On ALLO-329, questions focused on safety, infections, and the role of lymphodepletion; management said flu/Cy can drive immunocompetence down, reducing or eliminating it is a goal, and so far they have not seen anything concerning across CRS, ICANS, or infections.
The positive case from the call is that ALPHA3 appears to be gaining operational momentum, with rising MRD screening, stronger community interest, and brisk activity in Korea and Australia. Management sounded increasingly confident that cema-cel can work outside academic CAR-T centers, which could expand the addressable market if the safety and feasibility profile continues to hold.
The main risks are that ALPHA3 is still dependent on a long, complex registrational path and that the mid-2027 analysis may not produce a clean unblinded readout because only a small amount of alpha is allocated. For ALLO-329, the program remains very early, the next dataset is still pending, and management acknowledged that internal go/no-go decisions will depend on more than what is shown next week, including whether the safety and efficacy signals hold across different conditioning approaches.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.6%
- Shares Outstanding
- 346.47M
- Float Shares
- 258.56M
of shares held by institutions
216 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 30.93M | ▲ 780.38K |
| Frazier Life Sciences Management, L.P. | 22.45M | ▲ 18.65M |
| Pfizer Inc | 22.03M | 0 |
| Tpg Gp A, LLC | 18.72M | 0 |
| State Street Corp | 16.33M | ▼ 2.70M |
| Sio Capital Management, LLC | 13.32M | ▲ 13.32M |
| Primecap Management Co | 13.15M | ▲ 23.40K |
| Vanguard Capital Management LLC | 12.05M | ▼ 116.36K |
| Ubs Group AG | 10.70M | ▲ 7.67M |
| Fmr LLC | 10.60M | ▼ 1.41M |
| Citadel Advisors LLC | 10.09M | ▲ 3.29M |
| Vanguard Group Inc | 9.25M | ▲ 230.84K |
Held by 198 ETFs
Biggest fund positions in ALLO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 21, 26 | Parker Geoffrey M. | sell | 36,342 |
| Aug 21, 26 | Douglas Earl Martin | sell | 29,697 |
| Jul 1, 26 | Roberts Zachary | other | 476,190 |
| Jul 1, 26 | Roberts Zachary | other | 134,530 |
| Jun 18, 26 | Kazam Joshua A | other | 47,700 |
| Jun 18, 26 | Kazam Joshua A | other | 95,400 |
| Jun 18, 26 | Kazam Joshua A | other | 47,700 |
| Jun 18, 26 | MESSEMER DEBORAH M. | other | 95,400 |
| Jun 18, 26 | Mayo Stephen | other | 144,400 |
| Jun 18, 26 | SATO VICKI L | other | 95,400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALLO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ALLO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
globenewswire.com · Nov 20
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript
seekingalpha.com · Nov 9
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
globenewswire.com · Nov 9
Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Allogene Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
globenewswire.com · Nov 5
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
